- Home
- GMAB vs QSR Comparison
GMAB vs QSR Comparison
Compare GMAB & QSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- QSR
- Stock Information
- Founded
- GMAB 1999
- QSR 1954
- Country
- GMAB Denmark
- QSR United States
- Employees
- GMAB N/A
- QSR N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- QSR
- Sector
- GMAB Health Care
- QSR
- Exchange
- GMAB Nasdaq
- QSR Nasdaq
- Market Cap
- GMAB 17.4B
- QSR 20.6B
- IPO Year
- GMAB N/A
- QSR 2006
- Fundamental
- Price
- GMAB $33.17
- QSR $68.81
- Analyst Decision
- GMAB Strong Buy
- QSR Buy
- Analyst Count
- GMAB 7
- QSR 19
- Target Price
- GMAB $41.17
- QSR $75.39
- AVG Volume (30 Days)
- GMAB 2.0M
- QSR 3.3M
- Earning Date
- GMAB 11-05-2025
- QSR 11-05-2025
- Dividend Yield
- GMAB N/A
- QSR 3.62%
- EPS Growth
- GMAB 77.72
- QSR N/A
- EPS
- GMAB 21.62
- QSR 2.63
- Revenue
- GMAB $3,646,881,232.00
- QSR $9,106,000,000.00
- Revenue This Year
- GMAB $24.52
- QSR $11.58
- Revenue Next Year
- GMAB $15.53
- QSR $3.91
- P/E Ratio
- GMAB $14.83
- QSR $25.93
- Revenue Growth
- GMAB 32.97
- QSR 21.80
- 52 Week Low
- GMAB $17.24
- QSR $58.71
- 52 Week High
- GMAB $33.61
- QSR $74.09
- Technical
- Relative Strength Index (RSI)
- GMAB 81.44
- QSR 68.85
- Support Level
- GMAB $28.36
- QSR $64.11
- Resistance Level
- GMAB $29.52
- QSR $64.77
- Average True Range (ATR)
- GMAB 0.61
- QSR 1.16
- MACD
- GMAB 0.33
- QSR 0.62
- Stochastic Oscillator
- GMAB 92.06
- QSR 96.83
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About QSR Restaurant Brands International Inc.
Restaurant Brands International is one of the largest restaurant companies in the world, with approximately USD 44 billion in 2024 systemwide sales across a footprint that spanned more than 32,000 restaurants and more than 100 countries. The firm generates revenue primarily from retail sales at its company-owned restaurants, royalty fees and lease income from franchised stores, and from its Tim Hortons supply chain operations. Formed in 2014 after 3G Capital's acquisition of Tim Hortons International, the RBI portfolio is split among Burger King (7,082 units), Tim Hortons (4,539 units), Popeyes Louisiana Kitchen (3,520 units), Firehouse Subs (1,345 units), and international franchise units of those banners (15,639) as of year-end 2024.